AJANTPHARM.NS Profit & Loss
Ajanta Pharmaceuticals Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 21:33
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Revenue from Operations | ₹3,742.64 Cr. | ₹4,208.71 Cr. | ₹4,648.10 Cr. | ₹5,452.86 Cr. | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | N/A | N/A | N/A | N/A | SegmentRevenueFromOperations |
| Other Income | ₹98.64 Cr. | ₹84.60 Cr. | ₹94.50 Cr. | ₹172.07 Cr. | OtherIncome |
| Total Income | ₹3,841.28 Cr. | ₹4,293.31 Cr. | ₹4,742.60 Cr. | ₹5,624.93 Cr. | Income |
| Cost of Materials Consumed | ₹878.36 Cr. | ₹939.43 Cr. | ₹846.60 Cr. | ₹916.51 Cr. | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹146.28 Cr. | ₹166.35 Cr. | ₹249.80 Cr. | ₹229.79 Cr. | PurchasesOfStockInTrade |
| Changes in Inventories | ₹25.76 Cr. | ₹-39.21 Cr. | ₹-25.64 Cr. | ₹37.46 Cr. | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹785.14 Cr. | ₹900.34 Cr. | ₹1,089.69 Cr. | ₹1,291.15 Cr. | EmployeeBenefitExpense |
| Finance Costs | ₹5.84 Cr. | ₹7.21 Cr. | ₹20.73 Cr. | ₹16.11 Cr. | FinanceCosts |
| Depreciation and Amortisation | ₹130.80 Cr. | ₹135.40 Cr. | ₹144.11 Cr. | ₹173.14 Cr. | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹1,123.85 Cr. | ₹1,069.86 Cr. | ₹1,228.15 Cr. | ₹1,583.12 Cr. | OtherExpenses |
| Total Expenses | ₹3,096.03 Cr. | ₹3,179.38 Cr. | ₹3,553.44 Cr. | ₹4,247.28 Cr. | Expenses |
| Profit Before Exceptional Items and Tax | ₹745.25 Cr. | ₹1,113.93 Cr. | ₹1,189.16 Cr. | ₹1,377.65 Cr. | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹745.25 Cr. | ₹1,113.93 Cr. | ₹1,189.16 Cr. | ₹1,377.65 Cr. | ProfitBeforeTax |
| Tax Expense | ₹157.27 Cr. | ₹297.76 Cr. | ₹268.77 Cr. | ₹321.65 Cr. | TaxExpense |
| Net Profit (incl. minority interest) | ₹587.98 Cr. | ₹816.17 Cr. | ₹920.39 Cr. | ₹1,056.00 Cr. | ProfitLossForPeriod |
| Net Profit (to shareholders) | ₹0.00 Cr. | ₹816.98 Cr. | ₹920.39 Cr. | ₹1,056.00 Cr. | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹45.89 | ₹64.82 | ₹73.56 | ₹84.53 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹45.89 | ₹64.77 | ₹73.53 | ₹84.51 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from AJANTPHARM.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).